1. Missing puzzle pieces of time-restricted-eating (TRE) as a long-term weight-loss strategy in overweight and obese people? A systematic review and meta-analysis of randomized controlled trials
- Author
-
Jianfeng Yu, Bin Liu, Caiqun Ouyang, Feng Chen, Qian Ge, Xinying Zhang, Louise Weiwei Lu, Jie-Hua Chen, Dana Feng, and Ruijie Zhang
- Subjects
medicine.medical_specialty ,animal structures ,business.industry ,Subgroup analysis ,General Medicine ,Overweight ,medicine.disease ,Industrial and Manufacturing Engineering ,law.invention ,Randomized controlled trial ,law ,Weight loss ,Internal medicine ,Sarcopenia ,Weight management ,Lean body mass ,Medicine ,medicine.symptom ,business ,hormones, hormone substitutes, and hormone antagonists ,Dyslipidemia ,Food Science - Abstract
The efficacy of using time restricted eating (TRE) for weight management and to mitigate metabolic disorders in overweight and obese people remains debatable. This meta-analysis quantified the impact of TRE on weight loss and metabolic health in overweight and obese people. The pooled results were subjected to a random-effects modeling using Hartung-Knapp-Sidik-Jonkman (HKSJ) method. Additionally, subgroup analysis was conducted based on study types, randomized controlled trials (RCTs) vs. non-randomized studies of interventions (NRSIs). Pooled results showed that subjects on TRE regimen (> 4 weeks) achieved a significant weight loss in comparison with unrestricted time regimen (weighted mean difference: -2.32%; 95% CI: -3.50, -1.14%; p < 0.01); however, weight loss was mainly attributed to the loss of lean mass rather than fat mass. The magnitude of weight loss was inversely correlated with daily fasting duration in RCTs. TRE significantly decreased the diastolic blood pressure and fasting insulin. An increase of low-density lipoprotein cholesterol (LDL-C) was observed in the TRE group. Favorable effect of TRE was observed on glucose metabolism but not on lipid profiles independent of weight loss. Hence TRE shall be administered with caution to overweight and obese people who have comorbidities such as dyslipidemia and sarcopenia.
- Published
- 2021